Risperidone Therapy in a Dog with Dissociative Syndrome

Year 2018, Volume: 29 Issue: 1, 51 - 53, 30.04.2018

Duygu Dalğın Metin Çenesiz

Abstract

Recently describeddissociative syndrome is a progressive behavioral disorder with poor prognosis and almost 28% of animals do not seem to respond to the treatment. Inthe absence or lack of proper treatment, dissociation worsens and leads to severe cachexia. 4 years old Cocker spaniel-terrier mix male dog referred with complaints including receptivity loss to the environment, inattentiveness, dumb-looking periods, activity avoidance, withdrawal, and snapping the air as fly chasing without a reason. After elimination of somatic reasons, dissociative syndrome was diagnosed based on the history and behavioral examination. 0.5 ml Risperdal oral solution 1g/1m², 100 ml (Eczacıbaşı) was used sid based on 1 mg/m²dose for 11 kg dog (0.49 m²). Before and 1 month after therapy, serum serotonin and because of reported prolactin elevation, prolactin levels were measured. Before and after therapy, there was not a beyond reference value serotonin (370.5-441.9 ng/ml) and prolactin (1.8-2.1 ng/ml) difference. Significant clinical improvement, interactive and relatively increased receptivity and contact, not completely lost, but faded and decreased hallucitative symptoms were observed.

Keywords

Dissociative syndrome, Dog, Risperidone, Prolactin, Serotonin, Hallucination

Disosiyatif Sendromlu Bir Köpeğe Risperidon Tedavisi

Abstract

Son zamanlarda tanımlanan disosiyatif sendrom, prognozu kötü olan ilerleyici bir davranış bozukluğudur ve hayvanların neredeyse %28'inde tedaviye yanıt vermemektedir. Tedavi edilmez veya tedaviye cevap vermezse, durum kötüleşir ve ciddi kaşeksi oluşturur. Materyali, çevreye duyarsızlık kaybı, dikkatsizlik, aptal görünümlü dönemler, hareketsizlik, içine kapanma ve havada olmayan sineğin peşinden koşmak gibi şikayetleri olan 4 yaşında Cocker spaniel-terrier erkek köpek oluşturdu. Somatik nedenlerin ortadan kaldırılmasından sonra, öykü ve davranışsal inceleme temel alınarak dissosiyatif sendrom teşhis edildi. 11 kg köpek (0.49 m²) için 0.5 ml Risperdal oral solüsyon 1 g/1 m², 100 ml (Eczacıbaşı) kullanıldı. Tedaviden önce ve tedaviden 1 ay sonra serum serotonin ve prolaktin düzeyleri ölçüldü. Tedaviden önce ve sonra, referans değerden yüksek bir serotonin (370.5-441.9 ng / ml) ve prolaktin (1.8-2.1 ng/ml) görülmedi. Klinik olarak çevreye karşı ilginin artması, sosyalleşme ve dikkat toplamada düzelme tamamen kaybolmasa bile oldukça azalmış halüsitatif semptomları görülmüştür.

Keywords

Disosiyatif sendrom, Köpek, Risperidon, Prolaktin, Serotonin, Halüsinasyon

References

• Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M, Bergman RN (2005). Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: A placebo-controlled study of Olanzapine and Risperidone in dogs. Diabetes, 54 (3), 862-871. Beata CA (2001). Diagnosis and Treatment of Aggression in Dogs and Cats. In: Houpt KA (Ed), Recent Advances in Companion Animal Behavior Problems. International Veterinary Information Service (http://www.ivis.org), Ithaca, NY, Document No. A0808.1201. Corrada Y, Rimoldi I, Arreseigor S, Marecco G, Gobello C (2006). Prolactin reference range and pulsatility in male dogs. Theriogenology, 66, 1599–1602. DeLahunta A, Glass E (2009). Veterinary Neuroanatomy and Clinical Neurology: Saunders, Elsevier, Missouri, pp. 451. Landsberg GM, Hunthausen W, Ackerman L (2003). Handbook of Behavior Problems of the Dog and Cat. Second Edition, Saunders, Elsevier Health Sciences, Missuri, pp. 128, 472-474. Landsberg GM, Hunthausen W, Ackerman L (2012). Handbook of Behavior Problems of the Dog and Cat 3. Saunders, Elsevier Health Sciences, Missuri, pp. 166, 358-359, 420. Mannens G, Meuldermans W, Snoeck E, Heykants J (1994). Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology, 114(4), 566-72. Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, Le Jeune L, Lauwers W, Heykants J (1994). The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos, 22(1), 129-138. Pageat P (2012). Terminology, Behavioral Pathology and the Pageat (French) Approach to Canine Behavior Disorders. In: Landsberg G, Hunthausen W, Ackerman L (Eds), Handbook of Behavior Problems of the Dog and Cat. 3rd edition, Saunders, Elsevier Health Sciences, Missuri, pp. 359. Schotte A, Janssen PFM, Gommeren W (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology, 124, pp. 57–73. Thomas WB (2010). Idiopathic epilepsy in dogs& cats. Veterinary Clinics of North America: Small Animal Practice, 40, 161-179. Tian J, Wang W, Ye L, Cen X, Guan X, Zhang J, Yu P, Du G, Liu W, Li YA (2014). 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs. Hum Exp Toxicol, 33(5), 473-87.